Key result
Pre-existing neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 are prevalent in various animal models, with titers as low as 1/4 completely preventing in vivo AAV9 transduction in rats.
Pre-existing neutralizing antibodies against AAV vectors are prevalent in common animal models and can prevent in vivo transduction, necessitating prescreening in preclinical gene therapy studies.
Authors
No takes yet. Share an insight, caveat, or question.
Requires AAV antibody screening in cardiovascular animal models; challenges prior assumptions and leaves open reinterpretation of existing gene therapy data.
Rapti et al. (2011) studied Cardiovascular diseases (animal models). Pre-existing neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 was evaluated on Neutralizing antibody titers and in vivo transduction. Pre-existing neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 are prevalent in various animal models, with titers as low as 1/4 completely preventing in vivo AAV9 transduction in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: